ArticleHaematologica2023

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.

Kelden Richardson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.